Key Dates
May or June, 2022
Date
March, 2022
Abstract Submission Deadline
May or June, 2022
Online Registration Deadline
May or June, 2022
On-site Registration Dates

Registration/注册

Shengli Mi

报告题目:

Bio-fabrication, organ on chip,Tumor metastasis model

报告人:

Shengli Mi

所在单位:

Shenzhen International Graduate School, Tsinghua University.

Biography:


Shengli Mi, Associate Professor, Shenzhen International Graduate School, Tsinghua University. Shengli Mi currently serves as the the editorial board member of Biosensors, Biomaterials Translation, and the International Journal of ophthalmic research.He has published over 61 peer-reviewed journal papers such as Nature Communication, Biofabrication, Acta Biomaterialia, Drug Discovery Today, Soft Matter, Tissue Engineering Party A and Cell Research. 48 authorized patents. Mi Shengli's research mainly focuses on the development of bionic functional devices or tissues based on biological 3D printing, microfluidic control, MEMS and other technologies, especially in the development of ophthalmic bionic devices and ophthalmic medical instruments.



Abstract


Tumour invasion into the surrounding stroma is a critical step in metastasis, and it is necessary to clarify the role of microenvironmental factors in tumour invasion. We present a microfluidic system that simulated and controlled multi-factors of the tumour microenvironment for three-dimensional (3D) assessment of tumour invasion into the stroma. The simultaneous, precise and continuous arrangement of two 3D matrices was visualised to observe the migration of cancer cell populations or single cells by transfecting cells with a fluorescent protein. A vascular endothelial layer was formed to simulate transendothelial transport of nutrients, and its endothelial barrier function was verified by the diffusion of 70-kDa fluorescein isothiocyanate (FITC)-Dextran in 3D matrices. We clarified that cell density of the tumour directly determined its invasiveness. The results suggested that increased secretion of IL-6 among both cancer cells (MDA-MB-231) and non-cancerous cells (MCF-10A or HDF-n) after co-culture contributes to cancer cell invasiveness, and this was verified by an IL-6 inhibitor assay. Finally, the drug efficacy of paclitaxel was reflected as changes in cancer cell migration ability, viability, and morphology. Together, our microfluidic devices could be a useful tool to study the mechanism of tumour invasion into the stroma and to screen anti-metastatic drugs.